Cellectis S.A. Files Form 6-K with Press Release
Ticker: CLLS · Form: 6-K · Filed: Jun 12, 2024 · CIK: 1627281
| Field | Detail |
|---|---|
| Company | Cellectis S.A. (CLLS) |
| Form Type | 6-K |
| Filed Date | Jun 12, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release
TL;DR
Cellectis filed a 6-K on 6/12/24 with a press release attached. Details TBD.
AI Summary
Cellectis S.A. filed a Form 6-K on June 12, 2024, to report a press release dated June 12, 2024. The filing does not contain specific financial figures or operational updates beyond the announcement of the press release.
Why It Matters
This filing indicates that Cellectis S.A. has made a public announcement, which may contain important information for investors regarding the company's operations or strategic direction.
Risk Assessment
Risk Level: low — The filing is a routine report of a press release and does not contain new financial data or significant operational changes that would immediately impact risk.
Key Players & Entities
- Cellectis S.A. (company) — Registrant
- June 12, 2024 (date) — Filing date and press release date
FAQ
What is the subject of the press release filed by Cellectis S.A. on June 12, 2024?
The filing itself does not detail the content of the press release, only that it was issued on June 12, 2024, and is attached as Exhibit 99.1.
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, typically used to furnish information that the company makes or is required to make public in its home country.
Does this filing contain specific financial results for Cellectis S.A.?
No, this Form 6-K filing primarily serves to attach a press release and does not contain detailed financial results or operational updates within the filing itself.
What is Cellectis S.A.'s primary business according to the filing?
Cellectis S.A. is classified under the Standard Industrial Classification code 2836, which pertains to Biological Products (no diagnostic substances).
Where is Cellectis S.A. headquartered?
Cellectis S.A. is headquartered in Paris, France, with its principal executive office located at 8, rue de la Croix Jarry, 75013 Paris.
Filing Stats: 157 words · 1 min read · ~1 pages · Grade level 9.4 · Accepted 2024-06-12 16:35:05
Filing Documents
- f6k_061224.htm (6-K) — 4KB
- exh_991.htm (EX-99.1) — 9KB
- 0001171843-24-003413.txt ( ) — 14KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Cellectis S.A. (Registrant) Date: June 12, 2024 /s/ Andr Choulika Andr Choulika Chief Executive Officer